Biotek-snakken — December 2025
-
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 infla
Yahoo Finance (finance.yahoo.com)
-
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera h
Yahoo Finance (finance.yahoo.com)
-
Link til selskabspræsentation live med Pila Pharma kl. 12:00-12:20.
https://www.youtube.com/watch?v=A8sCT6dZc34 -
Jeg skrev et opslag om Curasight i dette forum tidligere i år da jeg mente at værdiansættelsen var blevet umotiveret lav efter den afsluttede emission (på det tidspunkt 150 mio. DKK). Siden da er aktien steget med flere hundrede procent i takt med, at triggere og studiedata for uTreat nærmer sig.
-
Jeg ser et potentielt lignende scenarie i Pila, som stadig handles tæt på emissionskursen og til en ekstremt lav værdiansættelse (100 mio. SEK) selv om en tydelig trigger i Gubra-studiet allerede venter i januar/februar. Ofte ser man meget kraftige udbrud i denne type undervurderede forskningsselskaber efter en afsluttet kapitalrejsning og forud for afgørende milepæle.
-
Ugevideo: Zealand Pharma, Genmab, Bavarian, Nanexa & Novo https://proinvestor.com/boards/130256
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind